Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
FAIL · Does not pass the screen
73.00 USD
Screen close, 2026-10-02 · not a live quote
Screened 2026-10-02 · the tape above runs as of 13:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 73.00 against the desk's fair-value range, base estimate 100.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price73.00 USD
Fair value100.00
Ethical score70.0/100
Our investment reviews on this name
2026-08-14Read Markup64.79+12.7% to today ✓
2026-07-02Read Distribution61.95+17.8% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Tarsus Pharmaceuticals, Inc. holds its Markup at $73.00. Consolidating, no directional conviction, held for 3 days.
As held on the ledger · 2026-10-02
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 3 days
Price at the screen
$73.00
Valuation
N/A trailing · -202.78 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.54
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
12.89%
Below 33%
Interest-bearing debt is just 12.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
41.56%
Below 33%
Interest-bearing cash and securities are 41.6% of assets, above the one-third limit.
Fail
Receivables
47.80%
Below 49%
Money owed to the company is 47.8% of assets, under the 49% limit.
Pass
Revenue purity
3.49%
Below 5%
Only 3.5% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Tarsus Pharmaceuticals,'s business is fine, but its cash and interest-bearing securities are about 42% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-02 screen. The gold marker is the market price at the same screen. A 37.0% margin of safety to the base estimate.
Third-party analyst targets: 10 covering, consensus Strong Buy. The average target sits +37% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-02 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
New Eyelid Drug Drives Triple Digit Sales
Demodex mites living on eyelids may sound niche until a single approved treatment starts pulling in serious revenue. Tarsus has posted 107% revenue growth from its XDEMVY launch yet still posts a negative 9% profit margin and negative 14% return on equity. Our fair value sits only 10% above the current price, which is why the opportunity rating stays at none despite the strong buy chorus from nine analysts.
The forward multiple of 36 times earnings already prices in further rapid expansion that has yet to reach consistent profits. An unknown moat leaves the business exposed once larger eye care players react. Ethical screen passes cleanly, yet the thin margin of safety keeps us on the sidelines.
High revenue growth in a commercial stage biotech rarely survives without eventual scale and positive returns on capital. Currency moves or reimbursement shifts could widen losses quickly. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TARS trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markup$78.09+10.5%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 10.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 49%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (9 analysts) rates it strong buy, with a mean price target of $94.
2026-09-14Markup$70.65+9.0%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 9.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 49%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (9 analysts) rates it strong buy, with a mean price target of $94.
2026-08-14Markup · changed$64.79+4.6%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 49%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (9 analysts) rates it strong buy, with a mean price target of $94.
2026-07-18Distribution$61.95+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 49%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (9 analysts) rates it strong buy, with a mean price target of $94.
2026-07-03Distribution$61.95+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Distribution$61.95Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
